- Home
- CD vs SIGA Comparison
CD vs SIGA Comparison
Compare CD & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CD | SIGA |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.2M | 421.8M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | CD | SIGA |
|---|---|---|
| Price | $7.39 | $6.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 232.0K | ★ 374.9K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | ★ 9.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | $956,830.00 | ★ $172,249,641.00 |
| Revenue This Year | $949,544.10 | N/A |
| Revenue Next Year | $14.69 | $132.36 |
| P/E Ratio | ★ N/A | $6.27 |
| Revenue Growth | ★ 65.39 | N/A |
| 52 Week Low | $1.38 | $4.95 |
| 52 Week High | $36.77 | $9.62 |
Technical Indicators
Market Signals| Indicator | CD | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.09 |
| Support Level | N/A | $6.13 |
| Resistance Level | N/A | $6.55 |
| Average True Range (ATR) | 0.00 | 0.21 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 0.00 | 86.81 |
Price Performance
Historical ComparisonAbout CD Chaince Digital Holdings Inc. Ordinary Shares
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.